Login / Signup

Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in the United States.

Rory Michael ShallisRong WangJan Philipp BewersdorfAmer M ZeidanAmy J DavidoffScott F HuntingtonNikolai A PodoltsevXiaomei Ma
Published in: Therapeutic advances in hematology (2021)
As expected, our findings highlight the frequent use of imatinib as the treatment option for older CML patients despite the availability of second-generation TKIs.
Keyphrases
  • chronic myeloid leukemia
  • end stage renal disease
  • newly diagnosed
  • ejection fraction
  • chronic kidney disease
  • peritoneal dialysis
  • physical activity
  • prognostic factors